Mayo Clinic Cancer Center and Yale Cancer Center/Smilow Cancer Hospital Named Newest NCCN Member InstitutionsContinue reading
Author Archive: AZBio
DxInsights to Host Diagnostics Summit
Forward-thinking Summit to be Held at the University of Arizona / Miraval InstituteContinue reading
What Our Community Can Do Together: AZBio’s CEO Looks Back and Forward
On March 21, 2011, I was granted the opportunity by AZBio’s Board of Directors to become our association’s president and ceo. What’s happened since then is a testament to what can happen when we come together as a community. —- Joan Koerber-WalkerContinue reading
Pinnacle Transplant Technologies Claims “Venture Madness” Crown
From a field of 64 early-stage companies emerged a single champion, Pinnacle Transplant Technologies, a multi-service tissue bank and client company of the Center for Entrepreneurial Innovation (CEI) at GateWay Community College.Continue reading
Tallwave expands competition to include Health IT
Tallwave today announced it is opening applications in its latest High Tide(TM) competition to Healthcare IT entrepreneurs from across the country. These entrepreneurs will join peers applying for the program in the previously announced focus on innovations in Ed Tech. In addition, Tallwave has reserved four to six slots for Arizona-only IT companies regardless of the industry sector they hail from. The deadline for submission is March 31, 2014 and can be completed online at www.tallwavehightide.com .Continue reading
UA Researchers Awarded Collaborative Flinn Foundation Grant to Unravel Lung Virome
Research team to study role of CMV persistence in the lung and its effect on the pulmonary virome, as well as translate findings to treatments.Continue reading
NATIONAL CAMPAIGN LAUNCHED TO HELP INCREASE DIVERSITY IN CLINICAL TRIALS
I’m In campaign to educate underrepresented populations about clinical trial participationContinue reading
Study Led by UA’s Dr. C. Kent Kwoh Finds Glucosamine Fails to Prevent Deterioration of Knee Cartilage, Decrease Pain
Findings indicate that glucosamine does not decrease pain or improve knee bone marrow lesions—thought to be a source of pain in those with osteoarthritis affecting 27 million Americans over age 25Continue reading
BIO Applauds CMS for Withdrawing Problematic Part D Proposals
March 10, 2014 – Washington DC – The Biotechnology Industry Organization (BIO) commended the Centers for Medicare & Medicaid Services (CMS) for announcing their decision to halt movement on several proposals in their Medicare Part D draft rule, including the agency’s proposal to eliminate protected class status for certain drug classes, as well as other proposals such as those related to reducing the number of Part D plans a particular plan sponsor may offer, and the proposal to clarify the non-interference provisions.Continue reading
Ventana and Bayer Extend Collaboration
Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into a multi-year agreement with Bayer Pharma AG (Bayer) to develop companion diagnostics, with a focus on immunohistochemistry (IHC), across Bayer’s portfolio of targeted therapy projects. This new agreement extends an already existing collaboration and focuses on the development of diagnostic tests for Bayer’s biomarker targeted therapeutics from early discovery through commercialization.Continue reading